Michael Barbella, Managing Editor03.25.24
The rising prevalence of hypertension in India has become a significant health concern, leading to serious health issues and increased mortality rates. Renal denervation has been emerging as one of the potential solutions to address these challenges, particularly for resistant hypertension. Consequently, the renal denervation catheters market in India is expected to grow 11% annually through 2033, forecasts GlobalData.
The company's report, “Renal Denervation Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that India’s renal denervation catheter market is expected to be worth about $2 million in 2033.
“The limited availability of therapeutic approaches for controlling resistant hypertension and preference for minimally invasive procedures are some of the factors driving the renal denervation catheters market in India," GlobalData Medical Devices Analyst Nandini Nagpal said. "The complexity of conventional renal denervation procedures restricts their effectiveness and accessibility across a wide spectrum of patients. This underscores the necessity for more innovative therapies to address hypertension more effectively.”
In December 2023, Medtronic introduced the Symplicity Spyral renal denervation system in India upon receiving U.S. Food and Drug Administration approval. This system offers patients a new adjunct way of lowering blood pressure through a catheter-based approach. It utilizes radiofrequency and supplements medications and lifestyle changes to assist in blood pressure reduction. It is claimed to be both safe and efficient, ensuring consistent blood pressure reductions for patients.
“Given the substantial burden of hypertension and the challenge of treatment-resistant cases in India, renal denervation offers a novel therapeutic approach. With the ongoing advancements in medical technology, including catheter design and targeting precision, coupled with the country's evolving healthcare infrastructure, renal denervation could find a useful application in medical centers across India,” Nagpal noted.
The company's report, “Renal Denervation Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that India’s renal denervation catheter market is expected to be worth about $2 million in 2033.
“The limited availability of therapeutic approaches for controlling resistant hypertension and preference for minimally invasive procedures are some of the factors driving the renal denervation catheters market in India," GlobalData Medical Devices Analyst Nandini Nagpal said. "The complexity of conventional renal denervation procedures restricts their effectiveness and accessibility across a wide spectrum of patients. This underscores the necessity for more innovative therapies to address hypertension more effectively.”
In December 2023, Medtronic introduced the Symplicity Spyral renal denervation system in India upon receiving U.S. Food and Drug Administration approval. This system offers patients a new adjunct way of lowering blood pressure through a catheter-based approach. It utilizes radiofrequency and supplements medications and lifestyle changes to assist in blood pressure reduction. It is claimed to be both safe and efficient, ensuring consistent blood pressure reductions for patients.
“Given the substantial burden of hypertension and the challenge of treatment-resistant cases in India, renal denervation offers a novel therapeutic approach. With the ongoing advancements in medical technology, including catheter design and targeting precision, coupled with the country's evolving healthcare infrastructure, renal denervation could find a useful application in medical centers across India,” Nagpal noted.